Interactions between the glycine transporter 1(GlyT1) inhibitor SSR504734 and psychoactive drugs in mouse motor behaviour

European Neuropsychopharmacology

Volumn 19, Issue 8, 2009, Pages 571-580

  Singer, Philipp ^a   Feldon, Joram ^a   Yee, Benjamin K ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Amphetamine; ; Antipsychotic; ; Dopamine; ; Glycine; ; NMDA; ; Schizophrenia

Indexed keywords

2 CHLORO N [ALPHA (2 PIPERIDINYL)BENZYL] 3 TRIFLUOROMETHYLBENZAMIDE; AMPHETAMINE; APOMORPHINE; DOPAMINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SPECIFICITY; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; MAZE TEST; MOTOR PERFORMANCE; MOUSE; NEUROMODULATION; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; SCHIZOPHRENIA;

AMPHETAMINE; ANIMALS; BENZAMIDES; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PHENCYCLIDINE; PILOT PROJECTS; PIPERIDINES; PSYCHOTROPIC DRUGS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 67349167781     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.02.004     Document Type: Article

References (70)

1. Angrist B.M. Amphtamine psychosis: clinical variations of the syndrome. In: Cho A.K., and Segal D.S. (Eds). Amphetamine and Its Analogues (1994), Academic Press, San Diego, CA 387-414
2. Angrist B.M., Peselow E., Rubinstein M., Corwin J., and Rotrosen J. Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology (Berl) 78 (1982) 128-130
3. Aragón C., and López-Corcuera B. Structure, function and regulation of glycine neurotransporters. Eur. J. Pharmacol. 479 (2003) 249-262
4. Arguello P.A., and Gogos J.A. Modeling madness in mice: one piece at a time. Neuron 52 (2006) 179-196
5. Baldessarini R.J., and Tarsy D. Pathophysiologic basis of tardive dyskinesia. Adv. Biochem. Psychopharm. 24 (1980) 451-455
6. Barch D.M., and Carter C.S. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr. Res. 77 (2005) 43-58
7. Bergeron R., Meyer T.M., Coyle J.T., and Greene R.W. Modulation of N-methyl-d-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15730-15734
8. Black, M.D., Varty, G.B., Arad, M., Barak, S., De Levie, A., Boulay, D., Pichat, P., Griebel, G., Weiner, I., 2009. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology 202, 385-396.
9. Boulay D., Pichat P., Dargazanli G., Estenne-Bouhtou G., Terranova J.P., Rogacki N., Stemmelin J., Coste A., Lanneau C., Desvignes C., Cohen C., Alonso R., Vigé X., Biton B., Steinberg R., Sevrin M., Oury-Donat F., George P., Bergis O., Griebel G., Avenet P., and Scatton B. Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol. Biochem. Behav. 91 (2008) 47-58
10. Breier A., Adler C., Weisenfeld N.I., Elman I., Picken L., Malhotra A.K., and Pickar D. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29 (1998) 142-147
11. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., Heresco-Levy U., and Carpenter W.T. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 164 (2008) 1593-1602
12. Carlsson A. Antipsychotic drugs and catecholamine synapses. J. Psychiatr. Res. 11 (1974) 57-64
13. Carlsson A. Receptor-mediated control of dopamine metabolism. In: Usdin E., and Bunney Jr. W.E. (Eds). Pre- and Post Synaptic Receptors (1975), Marcel Dekker, New York 49-67
14. Carlsson A. Does dopamine play a role in schizophrenia?. Psychol. Med. 7 (1977) 583-597
15. Chartoff E.H., Heusner C.L., and Palmiter R.D. Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. Neuropsychopharmacology 30 (2005) 1324-1333
16. Coyle J.T., and Tsai G. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int. Rev. Neurobiol. 59 (2004) 491-515
17. Cubelos B., Gimenez C., and Zafra F. Localization of the GlyT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb. Cortex 15 (2005) 448-459
18. Depoortère R., Dargazanli G., Estenne-Bouhtou G., Coste A., Lanneau C., Desvignes C., Poncelet M., Heaulme M., Santucci V., Decobert M., Cudennec A., Voltz C., Boulay D., Terranova J.P., Stemmelin J., Roger P., Marabout B., Sevrin M., Vigé X., Biton B., Steinberg R., Françon D., Alonso R., Avenet P., Oury-Donat F., Perrault G., Griebel G., George P., Soubrié P., and Scatton B. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30 (2005) 1963-1985
19. Di Chiara G., Porceddu M.L., Vargiu L., Argiolas A., and Gessa G.L. Evidence for dopamine receptors mediating sedation in the mouse brain. Nature 284 (1976) 564-566
20. Farber N.B. The NMDA receptor hypofunction model of psychosis. Ann. N.Y. Acad. Sc. 1003 (2003) 119-130
21. Gaisler-Salomon I., and Weiner I. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology 166 (2003) 333-342
22. Gaisler-Salomon I., Diamant L., Rubin C., and Weiner I. Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered. Psychopharmacology 196 (2008) 255-267
23. Gomeza J., Ohno K., and Betz H. Glycine transporter isoforms in the mammalian central nervous system: structures, functions and therapeutic promises. Curr. Opin. Drug Discov. Dev. 5 (2003) 675-682
24. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41 (1991) 1-24
25. Grace A.A. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res. Rev. 31 (2000) 330-341
26. Harsing Jr. L.G., Gacsalyi I., Szabo G., Schmidt E., Sziray N., Sebban C., Tesolin-Decros B., Matyus P., Egyed A., Spedding M., and Levay G. The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol. Biochem. Behav. 74 (2003) 811-825
27. Hashimoto K., Fujita Y., Ishima T., Chaki S., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and d-serine. Eur. Neuropsychopharmacol. 18 (2008) 414-421
28. Iversen S.D. Interactions between excitatory amino acids and dopamine systems in the forebrain: implications for schizophrenia and Parkinson's disease. Behav. Pharmacol. 6 (1995) 478-491
29. Javitt D.C. Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int. Rev. Neurobiol. 78 (2007) 69-108
30. Javitt D.C. Glycine transport inhibitors and the treatment of schizophrenia. Biol. Psychiatry 63 (2008) 6-8
31. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
32. Kelly P.H., Seviour P.W., and Iversen S.D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi andcorpus striatum. Brain Res. 94 (1975) 507-522
33. Kinney G.G., Sur C., Burno M., Mallorga P.J., Williams J.B., and Figueroa D.J. The glycine transporter type 1 inhibitor N-[3-(40-fluorophenyl)-3-(40-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J. Neurosci. 23 (2003) 7586-7591
34. Kirrane R.M., Mitropoulou V., Nunn M., New A.S., Harvey P.D., Schopick F., Silverman J., and Siever L.J. Effects of amphetamine on visuospatial working memory performance in schizophrenia spectrum personality disorder. Neuropsychopharmacology 22 (2000) 14-18
35. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., and Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch. Gen. Psychiatry 51 (1994) 199-214
36. Lane H.Y., Chang Y.C., Liu Y.C., Chiu C.C., and Tsai G.E. Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arvj. Gen. Psychiatry 62 (2005) 1196-1204
37. Lane H.Y., Huang C.L., Wu P.L., Liu Y.C., Chang Y.C., Lin P.Y., Chen P.W., and Tsai G. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol. Psychiatry 60 (2006) 645-649
38. Lane H.Y., Liu Y.C., Huang C.L., Chang Y.C., Liau C.H., Perng C.H., and Tsai G.E. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol. Psychiatry 63 (2008) 9-12
39. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res. Rev. 31 (2000) 371-384
40. Lechner S.M. Glutamate-based therapeutic approaches: inhibitors of glycine transport. Curr. Opin. Pharm. 6 (2006) 75-81
41. Leonetti M., Desvignes C., Bougault I., Souilhac J., Oury-Donat F., and Steinberg R. 2-Chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl benzamide, monohydrochloride, an inhibitor of the glycine transporter type 1, increases evoked-dopamine release in the rat nucleus accumbens in vivo via an enhanced glutamatergic neurotransmission. Neuroscience 137 (2006) 555-564
42. Lindsley C.W., Wolkenberg S.E., and Kinney G.G. Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors. Curr. Top. Med. Chem. 6 (2006) 1883-1896
43. Linn G.S., O'Keeffe R.T., Lifshitz K., Schroeder C., and Javitt D.C. Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine. Psychopharmacology (Berl) 192 (2007) 27-38
44. Lipina T., Labrie V., Weiner I., and Roder J. Modulators of the glycine site on NMDA receptors, d-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology 179 (2005) 54-67
45. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., and Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14 (1996) 301-307
46. Martina M., Gorfinkel Y., Halman S., Lowe J.A., Periyalwar P., Schmidt C.J., and Bergeron R. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J. Physiol. 557 (2004) 489-500
47. Meltzer H.Y., Sommers A.A., and Luchins D.J. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J. Clin. Psychopharmacol. 16 (1986) 329-338
48. Olivier B., Leahy C., Mullen T., Paylor R., Groppi V.E., and Sarnyai Z. The DBA/2J strain and prepulse inhibition of startle: amodel system to test antipsychotics?. Psychopharmacology 156 (2001) 284-290
49. Pinard E., Alberati D., Borroni E., Fischer H., Hainzl D., Jolidon S., Moreau J.L., Narquizian R., Nettekoven M., Norcross R.D., Stalder H., and Thomas A.W. Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. Bioorg. Med. Chem. Lett. 18 (2008) 5134-5139
50. Sanfilipo M., Wolkin A., Angrist B., van Kammen D.P., Duncan E., Wieland S., Cooper T.B., Peselow E.D., and Rotrosen J. Amphetamine and negative symptoms of schizophrenia. Psychopharmacology (Berl) 123 (1996) 211-214
51. Sershen H., Balla A., Aspromonte J.M., Xie S., Cooper T.B., and Javitt D.C. Characterization of interactions between phencyclidine and amphetamine in rodent prefrontal cortex and striatum: implications in NMDA/glycine-site-mediated dopaminergic dysregulation and dopamine transporter function. Neurochem. Int. 52 (2008) 119-129
52. Singer P., Feldon J., and Yee B.K. Interference of glycine transporter 1: modulation of cognitive functions via activation of Glycine-B site of the NMDA receptor. CNS Agents Med. Chem. 7 (2007) 259-268
53. Singer, P., Feldon, J., Yee, B.K., 2009. The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice. Psychopharmacology 202, 371-384.
54. Skirboll L.R., Grace A.A., and Bunney B.S. Dopamine auto- and postsynaptic receptors: electrophysiological evidence for differential sensitivity to dopamine agonists. Science 206 (1979) 80-82
55. Smith K.E., Borden L.A., Hartig P.R., Branchek T., and Weinshank R.L. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8 (1992) 927-935
56. Smith G.S., Schloesser R., Brodie J.D., Dewey S.L., Logan J., Vitkun S.A., Simkowitz P., Hurley A., Cooper R., Volkow N.D., and Cancro R. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 18 (1998) 18-25
57. Steinpreis R. The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modelling psychosis. Behav. Brain Res. 74 (1996) 45-55
58. Steinpreis R., and Salamone J.D. The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: a microdialysis and behavioral study. Brain Res. 612 (1993) 263-270
59. Strömbom U. Effects of low doses of catecholamine receptor agonists on exploration in mice. J. Neural Transm. 37 (1975) 229-235
60. Sur C., and Kinney G.G. Glycine transporter 1 inhibitors and modulation of NMDA receptor-mediated excitatory neurotransmission. Curr. Drug Targets 8 (2007) 643-649
61. Synder S.H. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am. J. Psychiatry 133 (1976) 197-202
62. Takahata R., and Moghaddam B. Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 28 (2003) 1117-1124
63. Tamminga C.A. Partial dopamine agonists in the treatment of psychosis. J. Neural Transm. 109 (2002) 411-420
64. Tamminga C.A., Schaffer M.H., Smith R.C., and Davis J.M. Schizophrenic symptoms improve with apomorphine. Science 200 (1978) 567-568
65. Tsai G., Lane H.Y., Yang P., Chong M.Y., and Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 55 (2004) 452-456
66. Tsai G., Ralph-Williams R.J., Martina M., Bergeron R., Berger-Sweeney J., Dunham K.S., Jiang Z., Caine S.B., and Coyle J.T. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc. Natl. Acad. Sci. USA 101 (2004) 8485-8490
67. Weiner I. Neural substrate of latent inhibition: the switching model. Psychol. Bull. 108 (1990) 442-461
68. Weiner I. The "two-headed" latent inhibition model of schizophrenia: modelling positive and negative symptoms and their treatment. Psychopharmacology 169 (2003) 257-297
69. Yee B.K., Hauser J., Dolgov V.V., Keist R., Möhler H., Rudolph U., and Feldon J. GABA receptors containing the alpha5 subunit mediate the trace effect in aversive and appetitive conditioning and extinction of conditioned fear. Eur. J. Neurosci. 20 (2004) 1928-1936
70. Yee B.K., Balic E., Singer P., Schwerdel C., Grampp T., Gabernet L., Knuesel I., Benke D., Feldon J., Mohler H., and Boison D. Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. J. Neurosci. 26 (2006) 3169-3181